What is Newland Pharmaceutical Co., Ltd.'s (301277.SZ) StockRank?

MoatMap's StockRank for Newland Pharmaceutical Co., Ltd. (301277.SZ) is 34/100, with a Sell signal. This is a composite score combining Quality (64), Value (35), and Momentum (28) factor ranks across MoatMap's 20,000+ stock universe.

Does Newland Pharmaceutical Co., Ltd. have an economic moat?

Newland Pharmaceutical Co., Ltd. (301277.SZ) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Newland Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Newland Pharmaceutical Co., Ltd. (301277.SZ) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Newland Pharmaceutical Co., Ltd. in?

Newland Pharmaceutical Co., Ltd. (301277.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301277.SZ

SELLREMOVE

Newland Pharmaceutical Co., Ltd. · Healthcare · China · $574M · Avg Vol: $3M/d

StockRank

P/E (TTM)

35.4x

ROE

6.2%

D/E

0.0x

Dividend %

2.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Newland Pharmaceutical lacks the global regulatory validation and scale to capture market share in the high-end CDMO space. It remains a generic-heavy business with limited pricing power.

COMPANY DESCRIPTION

Newland Pharmaceutical Co., Ltd. specializes in the R&D, production, and sale of steroid hormone active pharmaceutical ingredients (APIs) and intermediates. The company is a key player in the global steroid supply chain, utilizing advanced biological fermentation and green chemical synthesis technologies. Its competitive advantage is driven by its cost-efficient production of core intermediates like progesterone and dexamethasone.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	93M	96M	107M	99M	2.3%
EPS	—	0.06	0.06	0.07	0.05	-10.9%
Shares	—	392M	392M	392M	392M	0.0%
Debt	4M	845,583	401,785	440,566	841,189	-34.2%
Equity	—	200M	214M	228M	229M	4.6%
Op CF	—	12M	38M	19M	17M	12.2%
Inv CF	—	-113M	5M	-5M	-17M	—
Fin CF	—	103M	-10M	-12M	-17M	—

PRICE (1M)-20.9%

SMA 50SMA 200

$1.35

RSI (14)

23.1

52W High

$2.67

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

8.3%68.1

ROE

6.2%59.6

GP/Assets

11.5%28.7

Op. Margin

20.0%82.6

FCF/Assets

-1.9%44.1

Piotroski

—55.7

Int. Cover

50.0x91.4

D/E Ratio

0.00x95.6

Current Ratio

6.35x77.6

Value

P/E (TTM)

35.4x30.6

EV/EBITDA

19.2x20.0

P/FCF

—N/A

P/B

2.3x50.4

P/S

5.5x37.8

Div Yield

2.2%54.2

Momentum

52W High %

50%24.3

RS 6M

-33%36.8

SMA 50/200

0.89x31.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-36%15.9

FUNDAMENTALS

Market Cap

$574M

P/E (Forward)

—

Gross Margin

30.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301277.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301277.SZ	Newland Pharmaceutical Co., Ltd.(you)	$574M	34	SELL
688247.SS	Sinotherapeutics Inc.	$571M	32	SELL
300158.SZ	Shanxi Zhendong Pharmaceutical Co.,Ltd	$738M	34	SELL
002728.SZ	Teyi Pharmaceutical Group Co.,Ltd	$671M	32	SELL
002688.SZ	Jinhe Biotechnology CO., LTD.	$628M	38	HOLD
002793.SZ	Luoxin Pharmaceuticals Group Stock Co., Ltd.	$690M	31	SELL
002365.SZ	Qianjiang Yongan Pharmaceutical Co., Ltd.	$512M	28	SELL
300485.SZ	Beijing Science Sun Pharmaceutical Co., Ltd.	$634M	27	SELL
300194.SZ	Fuan Pharmaceutical (Group) Co., Ltd.	$672M	44	HOLD
300267.SZ	Hunan Er-Kang Pharmaceutical Co., Ltd	$1.1B	34	SELL

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.1%

Newland Pharmaceutical Co., Ltd. (301277.SZ) — Stock Score Summary

Newland Pharmaceutical Co., Ltd. (301277.SZ) has a MoatMap StockRank of 34/100 based on Quality (64/100), Value (35/100), and Momentum (28/100) factor scores. The current signal is SELL. Newland Pharmaceutical lacks the global regulatory validation and scale to capture market share in the high-end CDMO space. It remains a generic-heavy business with limited pricing power.

Key Financial Metrics

Price	$1.35
Market Cap	$574M
P/E (TTM)	35.42
Price/Book	2.28
Return on Equity	6.2%
Return on Invested Capital	8.3%
Debt/Equity	0.25
Gross Margin	30.9%
Operating Margin	20.0%
Revenue Growth	-5.8%
Dividend Yield	2.2%
Free Cash Flow	$-741K

Newland Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Newland Pharmaceutical Co., Ltd.’s (301277.SZ) StockRank?: MoatMap’s StockRank for Newland Pharmaceutical Co., Ltd. (301277.SZ) is 34/100, with a Sell signal. It is a composite of Quality (64), Value (35), and Momentum (28) factor ranks across MoatMap’s 20,000+ stock universe.
Does Newland Pharmaceutical Co., Ltd. have an economic moat?: Newland Pharmaceutical Co., Ltd. (301277.SZ) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Newland Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Newland Pharmaceutical Co., Ltd. (301277.SZ) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Newland Pharmaceutical Co., Ltd. in?: Newland Pharmaceutical Co., Ltd. (301277.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).